Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
NRIX Nurix Therapeutics	$11.62 +2.0%	$10.80	$8.18 ▼ $29.56	$885.86M	2.15	863,306 shs	491,613 shs
PHVS Pharvaris	$16.64 +0.5%	$16.30	$11.51 ▼ $25.50	$870.11M	-2.86	72,574 shs	6,244 shs
PRAX Praxis Precision Medicines	$42.97 -1.1%	$38.33	$26.70 ▼ $91.83	$875.26M	2.6	387,076 shs	254,896 shs
SLRN Acelyrin	$2.27	$2.29	$1.85 ▼ $7.25	$229.17M	1.07	1.27 million shs	N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
NRIX Nurix Therapeutics	0.00%	-2.84%	+14.60%	-10.55%	-36.98%
PHVS Pharvaris	0.00%	-3.42%	-3.54%	+8.05%	-13.87%
PRAX Praxis Precision Medicines	0.00%	-4.57%	+8.24%	+15.76%	+14.01%
SLRN Acelyrin	0.00%	0.00%	0.00%	-17.45%	-45.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
NRIX Nurix Therapeutics	1.2951 of 5 stars	3.4	1.0	0.0	0.0	1.7	0.8	0.0
PHVS Pharvaris	1.4051 of 5 stars	3.5	1.0	0.0	0.0	2.0	0.8	0.0
PRAX Praxis Precision Medicines	2.9033 of 5 stars	4.4	2.0	0.0	0.0	2.7	1.7	0.0
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
NRIX Nurix Therapeutics	2.83	Moderate Buy	$30.18	159.69% Upside
PHVS Pharvaris	3.00	Buy	$36.20	117.55% Upside
PRAX Praxis Precision Medicines	2.80	Moderate Buy	$109.90	155.76% Upside
SLRN Acelyrin	2.40	Hold	$9.60	322.91% Upside

Current Analyst Ratings Breakdown

Latest SLRN, NRIX, PRAX, and PHVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/11/2025	PHVS Pharvaris	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$32.00
6/5/2025	PHVS Pharvaris	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00
6/2/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform	$97.00
5/14/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$28.00 ➝ $25.00
5/7/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
5/5/2025	PRAX Praxis Precision Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$26.00 ➝ $28.00
5/5/2025	PRAX Praxis Precision Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/1/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $105.00
4/29/2025	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
4/29/2025	PHVS Pharvaris	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$28.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
NRIX Nurix Therapeutics	$54.55M	16.24	N/A	N/A	$7.44 per share	1.56
PHVS Pharvaris	N/A	N/A	N/A	N/A	$5.54 per share	N/A
PRAX Praxis Precision Medicines	$8.55M	102.37	N/A	N/A	$23.90 per share	1.80
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
NRIX Nurix Therapeutics	-$193.57M	-$2.80	N/A	N/A	N/A	-369.40%	-47.49%	-36.10%	7/10/2025 (Estimated)
PHVS Pharvaris	-$145.24M	-$3.01	N/A	N/A	N/A	N/A	-54.02%	-50.36%	8/13/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$10.72	N/A	N/A	N/A	-2,137.48%	-50.42%	-46.74%	8/12/2025 (Estimated)
SLRN Acelyrin	-$381.64M	-$2.69	N/A	N/A	N/A	N/A	-44.12%	-39.02%	8/12/2025 (Estimated)

Latest SLRN, NRIX, PRAX, and PHVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/10/2025	Q2 2025	NRIX Nurix Therapeutics	-$0.73	N/A	N/A	N/A	$16.26 million	N/A
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	PHVS Pharvaris	-$0.80	-$0.89	-$0.09	-$0.89	N/A	N/A
5/2/2025	Q1 2025	PRAX Praxis Precision Medicines	-$3.20	-$3.29	-$0.09	-$3.29	$0.20 million	N/A
4/8/2025	Q1 2025	NRIX Nurix Therapeutics	-$0.72	-$0.67	+$0.05	-$0.67	$12.78 million	$18.45 million
4/7/2025	Q4 2024	PHVS Pharvaris	-$0.74	-$0.68	+$0.06	-$0.68	N/A	N/A
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
NRIX Nurix Therapeutics	N/A	6.26	6.26
PHVS Pharvaris	N/A	11.10	11.10
PRAX Praxis Precision Medicines	N/A	8.44	8.44
SLRN Acelyrin	N/A	7.15	7.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
NRIX Nurix Therapeutics	N/A
PHVS Pharvaris	N/A
PRAX Praxis Precision Medicines	67.84%
SLRN Acelyrin	87.31%

Insider Ownership

Company	Insider Ownership
NRIX Nurix Therapeutics	7.40%
PHVS Pharvaris	11.84%
PRAX Praxis Precision Medicines	2.70%
SLRN Acelyrin	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
NRIX Nurix Therapeutics	300	76.24 million	70.60 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
PRAX Praxis Precision Medicines	110	20.37 million	19.82 million	Optionable
SLRN Acelyrin	135	100.95 million	86.68 million	Optionable

SLRN, NRIX, PRAX, and PHVS Headlines

Recent News About These Companies

Millennium Management LLC Sells 772,770 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

May 25, 2025 | marketbeat.com

132,870 Shares in Acelyrin, Inc. (NASDAQ:SLRN) Acquired by Stonepine Capital Management LLC

May 20, 2025 | marketbeat.com

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13, 2025 | globenewswire.com

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 6, 2025 | globenewswire.com

Acelyrin urges stockholders to vote for proposed merger with Alumis

May 2, 2025 | finance.yahoo.com

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025 | globenewswire.com

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025 | globenewswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

April 16, 2025 | businesswire.com

Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

Alumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

March 30, 2025 | morningstar.com

Insider Selling: Acelyrin, Inc. (NASDAQ:SLRN) Insider Sells 3,913 Shares of Stock

March 20, 2025 | insidertrades.com

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

March 18, 2025 | msn.com

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

March 13, 2025 | globenewswire.com

Acelyrin: Potential Buyout Led By Concentra Biosciences

March 12, 2025 | seekingalpha.com

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

March 7, 2025 | insidermonkey.com

ACELYRIN, INC.: ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | finanznachrichten.de

Acelyrin says Concentra indication not expected to result in superior proposal

March 4, 2025 | markets.businessinsider.com

Acelyrin falls as Acelyrin reaffirms deal commitment

March 4, 2025 | msn.com

Acelyrin, Alumis reaffirm strategic, financial rationale of proposed merger

March 4, 2025 | markets.businessinsider.com

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger

March 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLRN, NRIX, PRAX, and PHVS Company Descriptions

Nurix Therapeutics NASDAQ:NRIX

$11.62 +0.23 (+2.02%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$11.62 +0.01 (+0.04%)

As of 06/18/2025 04:39 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Pharvaris NASDAQ:PHVS

$16.64 +0.08 (+0.48%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$16.58 -0.06 (-0.36%)

As of 06/18/2025 04:04 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Praxis Precision Medicines NASDAQ:PRAX

$42.97 -0.49 (-1.13%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$42.98 +0.02 (+0.03%)

As of 06/18/2025 05:08 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Acelyrin NASDAQ:SLRN

$2.27 0.00 (0.00%)

As of 05/21/2025

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time